Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the findings of a study in which 140 patients with refractory gastrointestinal acute graft-versus-host disease (GI-aGvHD) were treated with pooled fecal allogeneic microbiotherapy as part of an early access program in Europe. The majority of patients were resistant to steroids and additional lines of treatment, namely ruxolitinib. Patients received three doses of MaaT013 as an enema, and the efficacy and safety of the therapy were assessed. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Participation in accredited CME/CPD: IACH, Medscape Oncology, WEBMD
Consultant/strategic advisor: Therakos, Gilead, Novatis, Bristol Myers Squibb, Sanofi, AstraZeneca, MSD, Jazz Pharmaceuticals​
Patents/shares or stocks related or unrelated to this presentation: None​
Non-financial interests: SAB MaaTPharma